Combined targeting of EGFR and HER2 against prostate cancer stem cells

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012 Jan;62(1):10–29. doi:10.3322/caac.20138.
   PubMed Web of Science ®Google Scholar
• Williams H, Powell IJ. Epidemiology, pathology, and genetics of prostate cancer among African Americans compared with other ethnicities. Methods Mol Biol. 2009;472:439–453. doi:10.1007/978-1-60327-492-0_21.
   PubMedGoogle Scholar
• Altavilla A, Iacovelli R, Procopio G, Alesini D, Risi E, Campenni GM, Palazzo A, Cortesi E. Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant. Cancer Biol Ther. 2012 Sep;13(11):1001–1008. doi:10.4161/cbt.21188.
   PubMed Web of Science ®Google Scholar
• DeHaan AM, Wolters NM, Keller ET, Ignatoski KM. EGFR ligand switch in late stage prostate cancer contributes to changes in cell signaling and bone remodeling. Prostate. 2009 Apr 1;69(5):528–537. doi:10.1002/pros.v69:5.
   PubMed Web of Science ®Google Scholar
• Traish AM, Morgentaler A. Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth. Br J Cancer. 2009 Dec 15;101(12):1949–1956. doi:10.1038/sj.bjc.6605376.
   PubMed Web of Science ®Google Scholar
• Berger R, Lin DI, Nieto M, Sicinska E, Garraway LA, Adams H, Signoretti S, Hahn WC, Loda M. Androgen-dependent regulation of Her-2/neu in prostate cancer cells. Cancer Res. 2006 Jun 1;66(11):5723–5728. doi:10.1158/0008-5472.CAN-05-3928.
   PubMed Web of Science ®Google Scholar
• Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med. 1999 Mar;5(3):280–285. doi:10.1038/6495.
   PubMed Web of Science ®Google Scholar
• Gregory CW, Whang YE, McCall W, Fei X, Liu Y, Ponguta LA, French FS, Wilson EM, Earp HS III. Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth. Clin Cancer Res. 2005 Mar 1;11(5):1704–1712. doi:10.1158/1078-0432.CCR-04-1158.
   PubMed Web of Science ®Google Scholar
• Wen Y, Hu MC, Makino K, Spohn B, Bartholomeusz G, Yan DH, Hung MC. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res. 2000 Dec 15;60(24):6841–6845.
   PubMed Web of Science ®Google Scholar
• Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci U S A. 1999 May 11;96(10):5458–5463. doi:10.1073/pnas.96.10.5458.
   PubMed Web of Science ®Google Scholar
• Shi Y, Brands FH, Chatterjee S, Feng AC, Groshen S, Schewe J, Lieskovsky G, Cote RJ. Her-2/neu expression in prostate cancer: high level of expression associated with exposure to hormone therapy and androgen independent disease. J Urol. 2001 Oct;166(4):1514–1519. doi:10.1016/S0022-5347(05)65822-3.
   PubMed Web of Science ®Google Scholar
• Signoretti S, Montironi R, Manola J, Altimari A, Tam C, Bubley G, Balk S, Thomas G, Kaplan I, Hlatky L, et al. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst. 2000 Dec 6;92(23):1918–1925. doi:10.1093/jnci/92.23.1918.
   PubMed Web of Science ®Google Scholar
• Morris MJ, Reuter VE, Kelly WK, Slovin SF, Kenneson K, Verbel D, Osman I, Scher HI. HER-2 profiling and targeting in prostate carcinoma. Cancer. 2002 Feb 15;94(4):980–986. doi:10.1002/(ISSN)1097-0142.
   PubMed Web of Science ®Google Scholar
• Neto AS, Tobias-Machado M, Wroclawski ML, Fonseca FL, Teixeira GK, Amarante RD, Wroclawski ER, Del GA. Her-2/neu expression in prostate adenocarcinoma: a systematic review and meta-analysis. J Urol. 2010 Sep;184(3):842–850. doi:10.1016/j.juro.2010.04.077.
   PubMed Web of Science ®Google Scholar
• Shah RB, Ghosh D, Elder JT. Epidermal growth factor receptor (ErbB1) expression in prostate cancer progression: correlation with androgen independence. Prostate. 2006 Sep 15;66(13):1437–1444. doi:10.1002/(ISSN)1097-0045.
   PubMed Web of Science ®Google Scholar
• Mimeault M, Batra SK. Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies. Carcinogenesis. 2006 Jan;27(1):1–22. doi:10.1093/carcin/bgi229.
   PubMed Web of Science ®Google Scholar
• Chen X, Rycaj K, Liu X, Tang DG. New insights into prostate cancer stem cells. Cell Cycle. 2013 Feb 15;12(4):579–586. doi:10.4161/cc.23721.
   PubMed Web of Science ®Google Scholar
• Schneider MR, Yarden Y. The EGFR-HER2 module: a stem cell approach to understanding a prime target and driver of solid tumors. Oncogene. 2016 Jun 9;35(23):2949–2960. doi:10.1038/onc.2015.372.
   PubMed Web of Science ®Google Scholar
• Mimeault M, Johansson SL, Vankatraman G, Moore E, Henichart JP, Depreux P, Lin MF, Batra SK. Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells. Mol Cancer Ther. 2007 Mar;6(3):967–978. doi:10.1158/1535-7163.MCT-06-0648.
   PubMed Web of Science ®Google Scholar
• Cho KH, Choi MJ, Jeong KJ, Kim JJ, Hwang MH, Shin SC, Park CG, Lee HY. A ROS/STAT3/HIF-1alpha signaling cascade mediates EGF-induced TWIST1 expression and prostate cancer cell invasion. Prostate. 2014 May;74(5):528–536. doi:10.1002/pros.22776.
   PubMed Web of Science ®Google Scholar
• Ripamonti F, Albano L, Rossini A, Borrelli S, Fabris S, Mantovani R, Neri A, Balsari A, Magnifico A, Tagliabue E. EGFR through STAT3 modulates deltaN63alpha expression to sustain tumor-initiating cell proliferation in squamous cell carcinomas. J Cell Physiol. 2013;228:871–878. doi:10.1002/jcp.24238.
   PubMed Web of Science ®Google Scholar
• Pencik J, Schlederer M, Gruber W, Unger C, Walker SM, Chalaris A, Marie IJ, Hassler MR, Javaheri T, Aksoy O, et al. STAT3 regulated ARF expression suppresses prostate cancer metastasis. Nat Commun. 2015 Jul 22;6:7736. doi:10.1038/ncomms8736.:7736.
   PubMed Web of Science ®Google Scholar
• Pisco AO, Huang S. Non-genetic cancer cell plasticity and therapy-induced stemness in tumour relapse: ‘What does not kill me strengthens me’. Br J Cancer. 2015 May 26;112(11):1725–1732. doi:10.1038/bjc.2015.146.
   PubMed Web of Science ®Google Scholar
• Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S, Reilly JG, Chandra D, Zhou J, Claypool K, et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene. 2006 Mar 16;25(12):1696–1708. doi:10.1038/sj.onc.1209327.
   PubMed Web of Science ®Google Scholar
• Rybak AP, He L, Kapoor A, Cutz JC, Tang D. Characterization of sphere-propagating cells with stem-like properties from DU145 prostate cancer cells. Biochim Biophys Acta. 2011 May;1813(5):683–694. doi:10.1016/j.bbamcr.2011.01.018.
   PubMed Web of Science ®Google Scholar
• Domingo-Domenech J, Vidal SJ, Rodriguez-Bravo V, Castillo-Martin M, Quinn SA, Rodriguez-Barrueco R, Bonal DM, Charytonowicz E, Gladoun N, del I, et al. Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. Cancer Cell. 2012 Sep 11;22(3):373–388. doi:10.1016/j.ccr.2012.07.016.
   PubMed Web of Science ®Google Scholar
• Mellinghoff IK, Tran C, Sawyers CL. Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts. Cancer Res. 2002 Sep 15;62(18):5254–5259.
   PubMed Web of Science ®Google Scholar
• Yin B, Liu Z, Wang Y, Wang X, Liu W, Yu P, Duan X, Liu C, Chen Y, Zhang Y, et al. RON and c-Met facilitate metastasis through the ERK signaling pathway in prostate cancer cells. Oncol Rep. 2017 Jun;37(6):3209–3218. doi:10.3892/or.2017.5585.
   PubMed Web of Science ®Google Scholar
• Lara PN Jr., Chee KG, Longmate J, Ruel C, Meyers FJ, Gray CR, Edwards RG, Gumerlock PH, Twardowski P, Doroshow JH, et al. Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California cancer consortium screening and phase II trial. Cancer. 2004 May 15;100(10):2125–2131. doi:10.1002/(ISSN)1097-0142.
   PubMed Web of Science ®Google Scholar
• Agus DB, Gordon MS, Taylor C, Natale RB, Karlan B, Mendelson DS, Press MF, Allison DE, Sliwkowski MX, Lieberman G, et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol. 2005 Apr 10;23(11):2534–2543. doi:10.1200/JCO.2005.03.184.
   PubMed Web of Science ®Google Scholar
• Agus DB, Sweeney CJ, Morris MJ, Mendelson DS, McNeel DG, Ahmann FR, Wang J, Derynck MK, Ng K, Lyons B, et al. Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. J Clin Oncol. 2007 Feb;25:675–681. doi:10.1200/JCO.2006.07.0649.
   PubMed Web of Science ®Google Scholar
• Blackledge G. Growth factor receptor tyrosine kinase inhibitors; clinical development and potential for prostate cancer therapy. J Urol. 2003 Dec;170(6 Pt 2):S77–S83. doi:10.1097/01.ju.0000095022.80033.d3.
   PubMed Web of Science ®Google Scholar
• Gross M, Higano C, Pantuck A, Castellanos O, Green E, Nguyen K, Agus DB. A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer. BMC Cancer. 2007 Jul 27;7:142–147. doi:10.1186/1471-2407-7-142.
   PubMed Web of Science ®Google Scholar
• Day KC, Lorenzatti HG, Kozminsky M, Dawsey SJ, Paul A, Broses LJ, Shah R, Kunja LP, Hall C, Palanisamy N, et al. HER2 and EGFR overexpression support metastatic progression of prostate cancer to bone. Cancer Res. 2017 Jan 1;77(1):74–85. doi:10.1158/0008-5472.CAN-16-1656.
   PubMed Web of Science ®Google Scholar
• Magnifico A, Albano L, Campaner S, Delia D, Castiglioni F, Gasparini P, Sozzi G, Fontanella E, Ménard S, Tagliabue E. Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to Trastuzumab. Clin Cancer Res. 2009;15:2010–2021. doi:10.1158/1078-0432.CCR-08-1327.
   PubMed Web of Science ®Google Scholar
• Korkaya H, Wicha MS. HER2 and breast cancer stem cells: more than meets the eye. Cancer Res. 2013 Jun 15;73(12):3489–3493. doi:10.1158/0008-5472.CAN-13-0260.
   PubMed Web of Science ®Google Scholar
• Schroeder A, Herrmann A, Cherryholmes G, Kowolik C, Buettner R, Pal S, Yu H, Muller-Newen G, Jove R. Loss of androgen receptor expression promotes a stem-like cell phenotype in prostate cancer through STAT3 signaling. Cancer Res. 2014 Feb 15;74(4):1227–1237. doi:10.1158/0008-5472.CAN-13-0594.
   PubMed Web of Science ®Google Scholar
• Cathomas R, Rothermundt C, Klingbiel D, Bubendorf L, Jaggi R, Betticher DC, Brauchli P, Cotting D, Droege C, Winterhalder R, et al. Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07). Clin Cancer Res. 2012 Nov 1;18(21):6049–6057. doi:10.1158/1078-0432.CCR-12-2219.
   PubMed Web of Science ®Google Scholar
• Nabhan C, Lestingi TM, Galvez A, Tolzien K, Kelby SK, Tsarwhas D, Newman S, Bitran JD. Erlotinib has moderate single-agent activity in chemotherapy-naive castration-resistant prostate cancer: final results of a phase II trial. Urology. 2009 Sep;74(3):665–671. doi:10.1016/j.urology.2009.05.016.
   PubMed Web of Science ®Google Scholar
• Liu G, Chen YH, Kolesar J, Huang W, Dipaola R, Pins M, Carducci M, Stein M, Bubley GJ, Wilding G. Eastern cooperative oncology group phase II trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer. Urol Oncol. 2013 Feb;31(2):211–218. doi:10.1016/j.urolonc.2011.01.002.
   PubMed Web of Science ®Google Scholar
• Bishop JL, Thaper D, Zoubeidi A. The multifaceted roles of STAT3 signaling in the progression of prostate cancer. Cancers (Basel). 2014 Apr 9;6(2):829–859. doi:10.3390/cancers6020829.
   PubMed Web of Science ®Google Scholar
• Nguyen HN, Noss EH, Mizoguchi F, Huppertz C, Wei KS, Watts GFM, Brenner MB. Autocrine loop involving IL-6 family member LIF, LIF receptor, and STAT4 drives sustained fibroblast production of inflammatory mediators. Immunity. 2017 Feb 21;46(2):220–232. doi:10.1016/j.immuni.2017.01.004.
   PubMed Web of Science ®Google Scholar
• Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham DA, Glennie MJ, et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer. 2010 May 25;102(11):1555–1577. doi:10.1038/sj.bjc.6605642.
   PubMed Web of Science ®Google Scholar